These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 36285641)
21. PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer. Slootbeek PHJ; Overbeek JK; Ligtenberg MJL; van Erp NP; Mehra N Cancer Lett; 2023 Nov; 577():216367. PubMed ID: 37689306 [TBL] [Abstract][Full Text] [Related]
22. Development of PARP Inhibitors in Targeting Castration-Resistant Prostate Cancer. Mouw KW; Choudhury AD Cancer Treat Res; 2023; 186():103-124. PubMed ID: 37978133 [TBL] [Abstract][Full Text] [Related]
23. PARP inhibitors in prostate cancer: practical guidance for busy clinicians. VanderWeele DJ; Hussain M Clin Adv Hematol Oncol; 2020 Dec; 18(12):808-815. PubMed ID: 33406057 [TBL] [Abstract][Full Text] [Related]
24. Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations. McFarland TR; Kessel A; Swami U; Agarwal N Am J Transl Res; 2021; 13(7):7427-7439. PubMed ID: 34377227 [TBL] [Abstract][Full Text] [Related]
27. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer. Inderjeeth AJ; Topp M; Sanij E; Castro E; Sandhu S Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497408 [TBL] [Abstract][Full Text] [Related]
28. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? Catalano M; Lapucci A; Nobili S; De Gennaro Aquino I; Vascotto IA; Antonuzzo L; Villari D; Nesi G; Mini E; Roviello G Cancer Chemother Pharmacol; 2024 Jan; 93(1):1-9. PubMed ID: 37934252 [TBL] [Abstract][Full Text] [Related]
29. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Loehr A; Hussain A; Patnaik A; Bryce AH; Castellano D; Font A; Shapiro J; Zhang J; Sautois B; Vogelzang NJ; Chatta G; Courtney K; Harzstark A; Ricci F; Despain D; Watkins S; King C; Nguyen M; Simmons AD; Chowdhury S; Abida W Eur Urol; 2023 Mar; 83(3):200-209. PubMed ID: 36243543 [TBL] [Abstract][Full Text] [Related]
30. Olaparib for Metastatic Castration-Resistant Prostate Cancer. de Bono J; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Mehra N; Goessl C; Kang J; Burgents J; Wu W; Kohlmann A; Adelman CA; Hussain M N Engl J Med; 2020 May; 382(22):2091-2102. PubMed ID: 32343890 [TBL] [Abstract][Full Text] [Related]
31. The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management. Rao A; Antonarakis ES Expert Rev Anticancer Ther; 2022 Jul; 22(7):671-679. PubMed ID: 35594523 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Jang A; Sartor O; Barata PC; Paller CJ Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33233320 [TBL] [Abstract][Full Text] [Related]
33. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer. Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369 [No Abstract] [Full Text] [Related]
34. PARP inhibitors in castration-resistant prostate cancer. Tripathi A; Balakrishna P; Agarwal N Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972 [TBL] [Abstract][Full Text] [Related]